Results 21 to 30 of about 1,776 (189)

A Bioorthogonal TCO–Tetrazine-Based Pretargeted PET/NIRF Platform Enabling High-Contrast Tumor Imaging [PDF]

Pharmaceuticals
Objectives: Pretargeting strategies enhance the specificity and safety of radiopharmaceuticals by separating tumor targeting from radionuclide delivery. To address the rapid clearance and systemic exposure of directly labeled small-molecule agents, a DZ ...
Mingxing Huang, Weichen Wang, Qiao Yu, Yike Zhou, Yingwei Wang, Rang Wang, Xin Li, Yaojia Zhou, Yi Zhang, Rong Tian   +9 more
doaj   +2 more sources

Dual-locked targeted alpha-emitter enhanced tumor immunotherapy via Diels–Alder reaction-based self-immolative molecular cage strategy [PDF]

Military Medical Research
Background Targeted alpha therapy (TAT) has emerged as a promising strategy for cancer treatment by selectively delivering high linear energy transfer (LET) alpha-emitters to tumor cells while minimizing off-target toxicity.
Meng-Die Yang, Kang Fang, Xiao-Yi Zhang, Gang Yang, He-Qing Yi, Le Cai, Shan-Shan Qin, Xin-Da Yang, Rong Rong, Shuo Shi, Fei Yu   +10 more
doaj   +2 more sources

Inverse electron demand Diels-Alder click chemistry for pretargeted PET imaging and radioimmunotherapy [PDF]

Nature Protocols, 2021
This approach leverages the rapid, bio-orthogonal inverse electron demand Diels-Alder reaction between a radiolabeled tetrazine and a trans-cyclooctene-bearing antibody to enable pretargeted positron emission tomography imaging and endoradiotherapy in a ...
Carnazza, Kathryn E., Dayts, Eric J., Dewaele-Le Roi, Guillaume, Keinanen, Outi, Rodriguez, Cindy, Sarrett, Samantha M., Zeglis, Brian M.   +6 more
core   +4 more sources

In Vivo Pretargeted Imaging of HER2 and TAG-72 Expression Using the HaloTag Enzyme. [PDF]

Mol Pharm, 2017
A novel pretargeted SPECT imaging strategy based on the HaloTag enzyme has been evaluated for the first time in a living system. To determine the efficacy of this approach, two clinically relevant cancer biomarkers, HER2 and TAG-72, were selected to ...
Knight JC, Mosley M, Uyeda HT, Cong M, Fan F, Faulkner S, Cornelissen B.   +6 more
europepmc   +3 more sources

Pretargeted Immuno-PET Enables Monoclonal Antibody Imaging Beyond the Blood-Brain Barrier. [PDF]

Mol Pharm
Pretargeted PET imaging offers a powerful approach to improve nuclear imaging contrast and reduce systemic radiation exposure, yet its application in the brain has been limited by the blood-brain barrier (BBB). Here, we demonstrate, for the first time, successful pretargeted PET imaging of a brain target enabled by a bispecific antibody engineered for ...
Gustavsson T, Kustermann T, Hvass L, Wuensche TE, Clausen AS, Stotz S, Shalgunov V, Lopes van den Broek S, Knudsen GM, Aldana B, Ferri E, Cannazza G, Niewoehner J, Gobbi L, Honer M, Battisti UM, Kjaer A, Herth MM.   +17 more
europepmc   +3 more sources

Pretargeting in nuclear imaging and radionuclide therapy:Improving efficacy of theranostics and nanomedicines [PDF]

Biomaterials, 2018
Pretargeted nuclear imaging and radiotherapy have recently attracted increasing attention for diagnosis and treatment of cancer with nanomedicines. This is because it conceptually offers better imaging contrast and therapeutic efficiency while reducing the dose to radiosensitive tissues compared to conventional strategies.
Edem, Patricia E, Herth, Matthias M, Jørgensen, Jesper T, Kjaer, Andreas, Nørregaard, Kamilla, Shalgunov, Vladimir, Stéen, E Johanna L   +6 more
core   +4 more sources

Characterization of Structurally Diverse 18F‑Labeled d‑TCO Derivatives as a PET Probe for Bioorthogonal Pretargeted Imaging [PDF]

ACS Omega, 2023
Karuna Adhikari, Jonatan Dewulf, Christel Vangestel, Pieter Van der Veken, Sigrid Stroobants, Filipe Elvas, Koen Augustyns   +6 more
doaj   +2 more sources

A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer

Theranostics, 2016
The complementary nature of positron emission tomography (PET) and near-infrared fluorescence (NIRF) imaging makes the development of strategies for the multimodal PET/NIRF imaging of cancer a very enticing prospect.
Adumeau, Pierre, Agnew, Brian J., Brand, Christian, Carlin, Sean D., Carnazza, Kathryn E., Lewis, Jason S., Reiner, Thomas, Zeglis, Brian M.   +7 more
core   +3 more sources

Pretargeted Imaging for In Vivo Assessment of ASO Therapy Delivery in Alzheimer’s Disease [PDF]

Alzheimers Dement
Abstract Background Intrathecally (IT) delivered antisense oligonucleotides (ASOs) are promising therapies that can reduce tau pathology in Alzheimer’s Disease (AD). However, current plasma and CSF sampling methods to estimate brain tissue exposure of ASOs are inherently limited, hampering ASO clinical developmental plans.
Cook B, Pickel T, Amatruda M, Zhang Q, Nag S, Bolduc P, Beshr R, Morén A, Muste C, Datta P, Ochniewicz P, Meynaq Y, DuBois J, Klein S, Halldin C, Passamonti L, Kaliszczak M.   +16 more
europepmc   +4 more sources

Antibody-Based In Vivo Imaging of Central Nervous System Targets—Evaluation of a Pretargeting Approach Utilizing a TCO-Conjugated Brain Shuttle Antibody and Radiolabeled Tetrazines

Pharmaceuticals, 2022
Bioorthogonal pretargeted imaging using the inverse-electron-demand Diels–Alder (IEDDA) reaction between a tetrazine (Tz) and a trans-cyclooctene (TCO) represents an attractive strategy for molecular imaging via antibodies.
Christoph Bredack, Martin R. Edelmann, Edilio Borroni, Luca C. Gobbi, Michael Honer   +4 more
doaj   +1 more source